Proton Therapy Well-Tolerated for Low-Grade Gliomas

Share this content:

the Cancer Therapy Advisor take:

Patients with low-grade glioma were found to tolerate proton radiation therapy without difficultly, according to an article published online in the journal Cancer.

The study included 20 patients diagnosed with World Health Organization grade 2 glioma.  These 20 patients were determined to be eligible for proton radiation therapy at a dose of 54 Gy (relative biological effectiveness) in 30 fractions.

Results revealed that a small subset (6 patients) experienced new neuroendocrine dysfunction and 19 out of the 20 patients received direct irradiation of the hypothalamic-pituitary axis.  Overall, intellectual functioning was reported to be within normal range and remained stable over time.  Patients’ visuospatial ability, attention/working memory, and executive functioning were all within normal range as well.  Impairments were observed in eight patients regarding their neurocognitive functions of language, memory, and processing speed. 

However, there was no overall decline in patients’ cognitive functioning reported.  Furthermore, patient quality of life assessment remained constant over time.  At 3 years, the progression-free survival rate was 85%, while at 5 years it declined to 40%.

Cancer of Unknown Origin: A Diagnostic and Treatment Dilemma
Patients with low-grade glioma were found to tolerate proton radiation therapy without difficultly.
In this prospective study, the authors evaluated potential treatment toxicity and progression-free survival in patients with low-grade glioma who received treatment with proton radiation therapy.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs